MFM
MRNA icon

MD Financial Management’s Moderna MRNA Stock Holding History

MD Financial Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$2.94M Buy
+11,589
New +$3.39M 0.07% 113

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MD Financial Management's MRNA Position: Q4 2021 in Review

MD Financial Management opened a new position in Moderna (MRNA) in Q4 2021: 11,589 shares worth $2.94M. The stake represents 0.07% of the portfolio and ranks #113 among its holdings.

1,110 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • MD Financial Management held 11,589 shares of Moderna worth $2.94M as of Q4 2021.
  • Moderna was a new MD Financial Management position in Q4 2021.
  • Moderna made up 0.07% of MD Financial Management's portfolio in Q4 2021, its #113 holding.
  • 1,110 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on MD Financial Management's 13F filing for Q4 2021, filed 14 Feb 2022.